

INTERNEURON PHARMACEUTICALS INC
Form SC 13D/A
May 23, 2001

May 21, 2001

Electronic Transmittal

Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC 20549

Re: Interneuron Pharmaceuticals, Inc.

Dear Sir or Madam:

On behalf of J. Morton Davis and D.H. Blair Investment Banking Corp., transmitted herewith is an amended Schedule 13D reporting changes in beneficial ownership of the securities of the above-mentioned company.

Very truly yours,

/s/ David Selengut

David Selengut

DS:dv

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 23)

Edgar Filing: INTERNEURON PHARMACEUTICALS INC - Form SC 13D/A

Interneuron Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

460573108

(CUSIP Number)

David Selengut, Ellenoff, Grossman, Schole, & Cyruli, LLP
370 Lexington Avenue, New York, NY 10017 (212) 370-1300

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 21, 2001

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box [].

Check the following box if a fee is being paid with this statement []. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 4 pages

CUSIP No. 460573108

13D

Page 2 of 4 Pages

Edgar Filing: INTERNEURON PHARMACEUTICALS INC - Form SC 13D/A

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

J. Morton Davis

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []
(b) []

3 SEC USE ONLY

4 Source of Funds

See Item #3 herein.

5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES	7	SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER
	9	SOLE DISPOSITIVE POWER
	10	SHARED DISPOSITIVE POWER

5,146,487

0

5,146,487

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,146,487

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

12%

14 TYPE OF REPORTING PERSON*
IN

*SEE INSTRUCTIONS BEFORE FILLING OUT

Edgar Filing: INTERNEURON PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 460573108

13D

Page 3 of 4 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

D.H. Blair Investment Banking Corp.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []
(b) []

3 SEC USE ONLY

4 Source of Funds

See Item #3 herein.

5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 7 SOLE VOTING POWER
SHARES 5,096,331
BENEFICIALLY
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING
PERSON 9 SOLE DISPOSITIVE POWER
WITH 5,096,331

10 SHARED DISPOSITIVE POWER
0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,096,331

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Edgar Filing: INTERNEURON PHARMACEUTICALS INC - Form SC 13D/A

11.9%

14 TYPE OF REPORTING PERSON*
BD

*SEE INSTRUCTIONS BEFORE FILLING OUT

Page 4 of 4 Pages

J. Morton Davis and D.H. Blair Investment Banking Corp. ("Blair Investment"), (together, the "Reporting Parties") hereby amend the following in their statement on Schedule 13D relating to the common stock, \$.001 par value ("shares") of Interneuron Pharmaceuticals, Inc. (the "Issuer") as follows:

Item 5. (a) is hereby amended in its entirety as follows:

As of May 21, 2001, Mr. Davis may be deemed to beneficially own 5,146,487 shares or 12% of the Issuer's shares issued and outstanding as follows: (i) 50,156 shares owned directly by Mr. Davis and (ii) 5,096,331 shares owned by Blair Investment.

As of May 21, 2001, Blair Investment may be deemed to beneficially own 5,096,331 shares or 11.9% of the Issuer's shares as indicated in (ii) above.

This Amendment corrects certain information contained in Amendment #22.

Item 5. (b) is hereby amended in its entirety as follows:

Mr. Davis has the sole power to vote or to direct the vote, to dispose or to direct the disposition of those shares owned directly by him and those owned by Blair Investment.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Date: May 21, 2001
New York, New York

/s/ J. Morton Davis

J. Morton Davis

D.H. BLAIR INVESTMENT BANKING CORP.

Edgar Filing: INTERNEURON PHARMACEUTICALS INC - Form SC 13D/A

Date: May 21, 2001
New York, New York

/s/ David Nachamie
by _____
David Nachamie
Treasurer